Growth · Biotech
Vedanta Biosciences: Growth
Develops microbiome-based oral therapies for prevention of recurrent C. difficile infection
Funding history
Growth · This round$60M
Develops microbiome-based oral therapies for prevention of recurrent C. difficile infection